vs
Side-by-side financial comparison of Aeluma, Inc. (ALMU) and Insight Molecular Diagnostics Inc. (IMDX). Click either name above to swap in a different company.
Aeluma, Inc. is the larger business by last-quarter revenue ($1.3M vs $1.1M, roughly 1.1× Insight Molecular Diagnostics Inc.). Aeluma, Inc. runs the higher net margin — -145.7% vs -2015.4%, a 1869.7% gap on every dollar of revenue. On growth, Aeluma, Inc. posted the faster year-over-year revenue change (-21.1% vs -23.4%). Aeluma, Inc. produced more free cash flow last quarter ($-282.0K vs $-7.0M).
Aeluma, Inc. is a U.S.-headquartered technology firm focused on the design, development, and production of high-performance optoelectronic components and semiconductor products. Its core offerings include photonic sensors and laser diodes, serving the LiDAR, 5G/6G communication, industrial sensing, and automotive markets across North America and the Asia-Pacific region.
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
ALMU vs IMDX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $1.1M |
| Net Profit | $-1.9M | $-23.0M |
| Gross Margin | 27.8% | 42.5% |
| Operating Margin | -163.6% | -2057.5% |
| Net Margin | -145.7% | -2015.4% |
| Revenue YoY | -21.1% | -23.4% |
| Net Profit YoY | 36.0% | 31.5% |
| EPS (diluted) | $-0.11 | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | $1.1M | ||
| Q3 25 | $1.4M | $260.0K | ||
| Q2 25 | — | $518.0K | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $115.0K | ||
| Q2 24 | — | $104.0K | ||
| Q1 24 | — | $176.0K |
| Q4 25 | $-1.9M | $-23.0M | ||
| Q3 25 | $-1.5M | $-10.9M | ||
| Q2 25 | — | $-9.7M | ||
| Q1 25 | — | $-6.7M | ||
| Q4 24 | — | $-33.5M | ||
| Q3 24 | — | $-13.5M | ||
| Q2 24 | — | $-4.5M | ||
| Q1 24 | — | $-9.1M |
| Q4 25 | 27.8% | 42.5% | ||
| Q3 25 | 49.4% | 53.5% | ||
| Q2 25 | — | 67.6% | ||
| Q1 25 | — | 62.0% | ||
| Q4 24 | — | 40.0% | ||
| Q3 24 | — | 43.5% | ||
| Q2 24 | — | 48.1% | ||
| Q1 24 | — | 25.6% |
| Q4 25 | -163.6% | -2057.5% | ||
| Q3 25 | -116.1% | -4249.2% | ||
| Q2 25 | — | -1900.0% | ||
| Q1 25 | — | -318.0% | ||
| Q4 24 | — | -2262.9% | ||
| Q3 24 | — | -11752.2% | ||
| Q2 24 | — | -4453.8% | ||
| Q1 24 | — | -5265.3% |
| Q4 25 | -145.7% | -2015.4% | ||
| Q3 25 | -107.8% | -4174.6% | ||
| Q2 25 | — | -1880.7% | ||
| Q1 25 | — | -312.0% | ||
| Q4 24 | — | -2255.1% | ||
| Q3 24 | — | -11733.0% | ||
| Q2 24 | — | -4355.8% | ||
| Q1 24 | — | -5186.9% |
| Q4 25 | $-0.11 | $-0.75 | ||
| Q3 25 | $-0.09 | $-0.34 | ||
| Q2 25 | — | $-0.30 | ||
| Q1 25 | — | $-0.26 | ||
| Q4 24 | — | $-2.19 | ||
| Q3 24 | — | $-0.98 | ||
| Q2 24 | — | $-0.36 | ||
| Q1 24 | — | $-1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.6M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $40.8M | $-31.5M |
| Total Assets | $42.6M | $25.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.6M | $11.6M | ||
| Q3 25 | $25.9M | $18.7M | ||
| Q2 25 | — | $24.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $8.6M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | $40.8M | $-31.5M | ||
| Q3 25 | $40.9M | $-9.2M | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | $10.2M | ||
| Q4 24 | — | $-12.3M | ||
| Q3 24 | — | $9.7M | ||
| Q2 24 | — | $22.7M | ||
| Q1 24 | — | $11.6M |
| Q4 25 | $42.6M | $25.8M | ||
| Q3 25 | $42.7M | $43.9M | ||
| Q2 25 | — | $50.5M | ||
| Q1 25 | — | $60.4M | ||
| Q4 24 | — | $35.1M | ||
| Q3 24 | — | $70.2M | ||
| Q2 24 | — | $74.7M | ||
| Q1 24 | — | $71.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-251.0K | $-5.5M |
| Free Cash FlowOCF − Capex | $-282.0K | $-7.0M |
| FCF MarginFCF / Revenue | -22.2% | -616.7% |
| Capex IntensityCapex / Revenue | 2.4% | 129.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-251.0K | $-5.5M | ||
| Q3 25 | $-815.0K | $-4.5M | ||
| Q2 25 | — | $-6.3M | ||
| Q1 25 | — | $-5.9M | ||
| Q4 24 | — | $-5.4M | ||
| Q3 24 | — | $-5.5M | ||
| Q2 24 | — | $-6.0M | ||
| Q1 24 | — | $-3.8M |
| Q4 25 | $-282.0K | $-7.0M | ||
| Q3 25 | $-1.0M | $-5.6M | ||
| Q2 25 | — | $-6.6M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $-5.6M | ||
| Q2 24 | — | $-6.2M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | -22.2% | -616.7% | ||
| Q3 25 | -74.0% | -2135.4% | ||
| Q2 25 | — | -1279.5% | ||
| Q1 25 | — | -288.4% | ||
| Q4 24 | — | -374.5% | ||
| Q3 24 | — | -4884.3% | ||
| Q2 24 | — | -5931.7% | ||
| Q1 24 | — | -2189.8% |
| Q4 25 | 2.4% | 129.9% | ||
| Q3 25 | 15.2% | 403.8% | ||
| Q2 25 | — | 67.4% | ||
| Q1 25 | — | 14.4% | ||
| Q4 24 | — | 14.4% | ||
| Q3 24 | — | 75.7% | ||
| Q2 24 | — | 183.7% | ||
| Q1 24 | — | 13.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
